RYAN
2.12.2021 08:02:10 CET | Business Wire | Press release
Ryan , a leading global tax services and software provider, today announced the acquisition of Qvalia’s value added tax (VAT) compliance and recovery business. As a major market provider of VAT services in the Nordics, this acquisition significantly expands Ryan’s brand in the region and continues to strengthen and grow its service offerings across Europe.
“Ryan’s commitment to our clients in the European region is evident by our expansion into the Nordics,” said Ryan Chairman and CEO G. Brint Ryan . “We’re thrilled to welcome Qvalia’s highly experienced tax professionals to our workplace. Our clients will benefit from Qvalia’s leading VAT recovery and compliance services in the Nordics, while Qvalia’s clients can now take advantage of Ryan’s full suite of tax services globally, creating tax centres of excellence.”
Founded in 2007, with headquarters in Stockholm, Sweden and offices in Norway, Finland, and Denmark, Qvalia has helped the region’s largest organisations analyse accounting data, manage costs, reduce risks, and improve the entire tax process. This strategic acquisition adds 32 highly qualified VAT professionals, located across four new office locations to Ryan’s European team, including Qvalia’s four senior country leaders: Michael Bernhardtsen in Denmark, Andre Klemsdal in Norway, Teemu Kamu in Finland, and Cathrine Engman in Sweden. Collectively, with more than 40 years of experience, they will focus on Ryan’s growth trajectory in their respective country markets, bringing additional value to their existing clients.
“The addition of Qvalia’s VAT compliance and recovery team further solidifies Ryan as a leading provider of VAT services in Europe. Qvalia’s innovative and transformative approach and culture are a powerful fit with our mission to help our clients transform their tax function into centers of excellence,” said Jon C. Sweet, Ryan’s President of European and Asia-Pacific Operations . “This acquisition not only positions Ryan as the preeminent VAT provider in the Nordics, but it also strengthens our VAT compliance and recovery practice throughout Europe.”
Qvalia’s finance process automation platform and fintech will continue to operate under the Qvalia name and brand and will not be included as part of the acquisition. With significant synergies existing between the two companies, there will be continued opportunities for both Qvalia’s and Ryan’s combined client base to leverage discreet offerings, as the two organisations partner prospectively.
“This is an exciting opportunity for Qvalia’s VAT compliance and recovery team to join a global leading tax firm. After founding and growing this practice over the last 15 years, I am confident this team will bring valuable in-depth knowledge, expertise, and experience of the Nordic market to Ryan,” said Henri Taipale, CEO and founder of Qvalia, who will be focusing on further growing Qvalia’s finance process automation platform. “I am looking forward to continuing to partner with Ryan and joining forces to be able to serve our mutual clients in an excellent and innovative way.”
About Ryan
Ryan, an award-winning global tax services and software provider, is the largest Firm in the world dedicated exclusively to business taxes. The Firm provides an integrated suite of international tax services on a multijurisdictional basis, including cost management, compliance, consulting, and technology services. Ryan is a nine-time recipient of the International Service Excellence Award from the Customer Service Institute of America (CSIA) for its commitment to world-class client service. Empowered by the dynamic myRyan work environment, which is widely recognised as the most innovative in the tax services industry, Ryan’s multidisciplinary team of more than 3,100 professionals and associates serves over 18,000 clients in more than 60 countries, including many of the world’s most prominent Global 5000 companies. More information about Ryan can be found at ryan.com/europe. “Ryan” and “Firm” refer to the global organisational network and may refer to one or more of the member firms of Ryan International, each of which is a separate legal entity.
About Qvalia
Qvalia redesigns finance processes. Founded in 2007, the company expanded to become the leading Nordic expert in financial data mining. Since 2017, the company has developed a platform for finance teams to automate financial processes, including e-invoicing, accounting, and analytics. The company has offices in Stockholm, Helsinki, Copenhagen, and Oslo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201006097/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom